Jiang Ting, Gao Chen, Luo Yiyang, Ye Zixiang, Wang Binbin
Department of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Department of Oncology, The First Affiliated Rehabilitation Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
Onco Targets Ther. 2022 Aug 25;15:883-890. doi: 10.2147/OTT.S369772. eCollection 2022.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most fatal diseases, with its morbidity and mortality showing an upward trend. The application of monotonous immune checkpoint inhibitor (ICI) in PDAC comes to a disappointing endpoint, despite of its great advancements achieved in cancer treatment. However, a promising efficacy can be obtained on condition that ICIs are used in combination with chemotherapy.
We reported a patient suffering from metastatic PDAC with proficient mismatch repair (pMMR) and low expression of programmed cell death ligand 1 (PD-L1). The patient survived for a remarkably long time and showed favorable tolerance to the combination of FOLFIRINOX+Toripalimab (a novel PD-1 inhibitor) administrated after chemoradiotherapy and targeted therapy. Today, the survival benefits gained from this therapy will continue to have a positive impact on him.
FOLFIRINOX+Toripalimab potentially serves as a novel therapeutic strategy for PDAC in late stage, with durable benefits and manageable toxicity in patients, which is still required to be validated in further research.
胰腺导管腺癌（PDAC）仍然是最致命的疾病之一，其发病率和死亡率呈上升趋势。尽管免疫检查点抑制剂（ICI）在癌症治疗方面取得了巨大进展，但在PDAC中应用单一ICI却得出了令人失望的结果。然而，如果ICI与化疗联合使用，则可以获得有前景的疗效。
我们报告了一名患有转移性PDAC的患者，该患者错配修复功能正常（pMMR）且程序性细胞死亡配体1（PD-L1）低表达。该患者存活了很长时间，并且对放化疗和靶向治疗后给予的FOLFIRINOX+托瑞帕利单抗（一种新型PD-1抑制剂）联合治疗表现出良好的耐受性。如今，这种治疗带来的生存益处将继续对他产生积极影响。
FOLFIRINOX+托瑞帕利单抗可能是晚期PDAC的一种新型治疗策略，对患者具有持久的益处且毒性可控，这仍需要在进一步研究中得到验证。
